Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Peptic Ulcer

Free Subscription Articles published in Am J Gastroenterol Retrieve available abstracts of 70 articles: HTML format

Single Articles

November 2023
1. BUJANDA L, Nyssen OP, Ramos J, Bordin DS, et al
   Effectiveness of Helicobacter pylori treatments according to antibiotic resistance.
   Am J Gastroenterol. 2023 Nov 17. doi: 10.14309/ajg.0000000000002600.
   PubMed     Abstract available
   
   
   
2. YAN TL, Wang JH, He XJ, Zhu YB, et al
   Ten-day vonoprazan-amoxicillin dual therapy versus standard fourteen-day Bismuth-based quadruple therapy for first-line Helicobacter pylori eradication: a multicenter randomized clinical trial.
   Am J Gastroenterol. 2023 Nov 17. doi: 10.14309/ajg.0000000000002592.
   PubMed     Abstract available
   
   
   
3. ZULLO A, Gatta L, De Francesco V
   Randomized Controlled Trials for Helicobacter pylori Infection: What We Should Compare.
   Am J Gastroenterol. 2023;118:2094.
   PubMed    
   
   
   
4. KOUNTOURAS J
   Thinking of the Long Puzzling Issue of Several Suboptimal Treatments of Helicobacter pylori Infection.
   Am J Gastroenterol. 2023;118:2093.
   PubMed    
   
   
   September 2023
5. SHUNG DL, Lin JK, Laine L
   Achieving Value by Risk Stratification with Machine Learning Model or Clinical Risk Score in Acute Upper Gastrointestinal Bleeding: A Cost Minimization Analysis.
   Am J Gastroenterol. 2023 Sep 27. doi: 10.14309/ajg.0000000000002520.
   PubMed     Abstract available
   
   
   August 2023
6. TAPPER EB, Zhao Z, Parikh ND
   An emulated clinical trial of deprescribing proton pump inhibitors in patients with cirrhosis.
   Am J Gastroenterol. 2023 Aug 10. doi: 10.14309/ajg.0000000000002462.
   PubMed     Abstract available
   
   
   June 2023
7. GREENAN G, Rogers BD, Gyawali CP
   PROXIMAL GASTRIC PRESSURIZATION FOLLOWING SLEEVE GASTRECTOMY ASSOCIATES WITH GASTROESOPHAGEAL REFLUX.
   Am J Gastroenterol. 2023 Jun 19. doi: 10.14309/ajg.0000000000002374.
   PubMed     Abstract available
   
   
   
8. CORAZZIARI ES, Gasbarrini A, D'Alba L, D'Ovidio V, et al
   Poliprotect vs Omeprazole in the relief of heartburn, epigastric pain and burning in patients without erosive esophagitis and gastro-duodenal lesions: A Randomized, Controlled Trial.
   Am J Gastroenterol. 2023 Jun 13. doi: 10.14309/ajg.0000000000002360.
   PubMed     Abstract available
   
   
   May 2023
9. GRAHAM DY
   It Is Time for a Paradigm Shift in Design, Execution, and Publishing of Comparative Helicobacter pylori Treatment Trials.
   Am J Gastroenterol. 2023 May 15. doi: 10.14309/ajg.0000000000002298.
   PubMed    
   
   
   
10. CHITTAJALLU V, Vozzo C, Friedman K, Glessing B, et al
    Odynophagia Secondary to Mpox-Associated Esophageal Ulceration.
    Am J Gastroenterol. 2023;118:774.
    PubMed    
    
    
    March 2023
11. HSU PI, Chen KY, Tai WC, Yang JC, et al
    Hybrid, high-dose dual and bismuth quadruple therapies for first-line treatment of Helicobacter pylori infection in Taiwan: a multicenter, open-label, randomized trial.
    Am J Gastroenterol. 2023 Mar 20. doi: 10.14309/ajg.0000000000002255.
    PubMed     Abstract available
    
    
    
12. DENG C, Wu S, Xu F, Zhou Z, et al
    Underwater anti-reflux mucosectomy for refractory gastroesophageal reflux disease:A rapid and simple technique for endoscopic treatment.
    Am J Gastroenterol. 2023 Mar 20. doi: 10.14309/ajg.0000000000002256.
    PubMed    
    
    
    January 2023
13. YUNUSA I, Love BL
    Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs. Other Regimens as First-Line Treatment of Helicobacter pylori Infection in the United States.
    Am J Gastroenterol. 2023 Jan 25. doi: 10.14309/ajg.0000000000002146.
    PubMed     Abstract available
    
    
    
14. CUMMINGS LC, Hojat LS, Nguyen DC, Stempak LM, et al
    Tailored Treatment Based on Helicobacter pylori Genetic Markers of Resistance Is Associated With Higher Eradication Success.
    Am J Gastroenterol. 2023 Jan 6. doi: 10.14309/ajg.0000000000002085.
    PubMed     Abstract available
    
    
    December 2022
15. VISAGGI P, Del Corso G, Gyawali CP, Ghisa M, et al
    Ambulatory pH-Impedance Findings Confirm that Grade B Esophagitis Provides Objective Diagnosis of Gastroesophageal Reflux Disease.
    Am J Gastroenterol. 2022 Dec 29. doi: 10.14309/ajg.0000000000002173.
    PubMed     Abstract available
    
    
    
16. ROSEN R
    Gastroesophageal reflux treatment in infancy through young adulthood.
    Am J Gastroenterol. 2022 Dec 24. doi: 10.14309/ajg.0000000000002160.
    PubMed     Abstract available
    
    
    
17. QIAN HS, Li WJ, Dang YN, Li LR, et al
    Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
    Am J Gastroenterol. 2022 Dec 2. doi: 10.14309/ajg.0000000000002086.
    PubMed     Abstract available
    
    
    November 2022
18. RUBENSTEIN JH
    Gastroesophageal Reflux Disease Is Not a Great Screening Criterion: Time to Move on to Other Strategies for Controlling the Burden of Esophageal Adenocarcinoma.
    Am J Gastroenterol. 2022;117:1759-1761.
    PubMed     Abstract available
    
    
    October 2022
19. KAMAL AN, Wang CJ, Triadafilopoulos G, Clarke JO, et al
    Healthcare Disparities in Gastroesophageal Reflux Disease for Hispanic and Latino Americans: A Solution-Oriented Approach for Improvement.
    Am J Gastroenterol. 2022 Oct 7. pii: 00000434-990000000-00479.
    PubMed    
    
    
    
20. GU C, Olszewski T, King KL, Vaezi MF, et al
    The Effects of Modifying Amount and Type of Dietary Carbohydrate on Esophageal Acid Exposure Time and Esophageal Reflux Symptoms: A Randomized Controlled Trial.
    Am J Gastroenterol. 2022;117:1655-1667.
    PubMed     Abstract available
    
    
    September 2022
21. MEGRAUD F, Graham DY, Howden CW, Trevino E, et al
    Rates of Antimicrobial Resistance in Helicobacter pylori Isolates from Clinical Trial Patients Across the US and Europe.
    Am J Gastroenterol. 2022 Sep 30. pii: 00000434-990000000-00527.
    PubMed     Abstract available
    
    
    
22. ELHENCE A, Ghoshal UC
    Sleep Position and Reflux: Do Not Lose Sleep Over It.
    Am J Gastroenterol. 2022;117:1539.
    PubMed    
    
    
    August 2022
23. HASEEB M, McCarty TR, Jirapinyo P, Thompson CC, et al
    Letter to the Editor in Response to ACG Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease.
    Am J Gastroenterol. 2022 Aug 23. pii: 00000434-990000000-00481.
    PubMed    
    
    
    July 2022
24. ZHOU Y
    Proton Pump Inhibitors and Risk of Mortality: Longer and More Dangerous?
    Am J Gastroenterol. 2022;117:1171-1172.
    PubMed    
    
    
    June 2022
25. YADLAPATI R, Gyawali CP, Masihi M, Carlson DA, et al
    OPTIMAL WIRELESS REFLUX MONITORING METRICS TO PREDICT DISCONTINUATION OF PROTON PUMP INHIBITOR THERAPY: Optimal Reflux Monitoring Metrics to Predict PPI Discontinuation.
    Am J Gastroenterol. 2022 Jun 10. pii: 00000434-990000000-00403.
    PubMed     Abstract available
    
    
    
26. AZHARI H, King JA, Coward S, Windsor JW, et al
    The Global Incidence of Peptic Ulcer Disease is Decreasing since the Turn of the 21st Century: A Study of the Organisation for Economic Co-operation and Development (OECD): Global Incidence of Peptic Ulcer Disease.
    Am J Gastroenterol. 2022 Jun 2. pii: 00000434-990000000-00385.
    PubMed     Abstract available
    
    
    
27. WANG R, Bai D, Xiang W, Chen XZ, et al
    Tibetan Ethnicity, Birthplace, Helicobacter pylori Infection, and Gastric Cancer Risk.
    Am J Gastroenterol. 2022;117:1010.
    PubMed    
    
    
    May 2022
28. HO JJC, Navarro M, Sawyer K, Elfanagely Y, et al
    Helicobacter pylori Antibiotic Resistance in the United States Between 2011-2021: A Systematic Review and Meta-Analysis.
    Am J Gastroenterol. 2022 May 5. pii: 00000434-990000000-00369.
    PubMed     Abstract available
    
    
    
29. PARK JY, Yoo J, Jeon J, Kim J, et al
    Proton pump inhibitors and risk of cardiovascular disease: a self-controlled case series study.
    Am J Gastroenterol. 2022 May 4. pii: 00000434-990000000-00361.
    PubMed     Abstract available
    
    
    April 2022
30. DEWITT J, Kessler W, Wo J, Stainko S, et al
    SYMPTOM ASSOCIATION FOR GASTROESOPHAGEAL REFLUX DISEASE BY PH MONITORING AFTER PERORAL ENDOSCOPIC MYOTOMY: GERD and symptoms after POEM.
    Am J Gastroenterol. 2022 Apr 25. pii: 00000434-990000000-00351.
    PubMed     Abstract available
    
    
    March 2022
31. VENKAT PG, Longstreth GF
    Gastroesophageal Reflux Disease and the Zollinger-Ellison Syndrome.
    Am J Gastroenterol. 2022 Mar 28. pii: 00000434-990000000-00307.
    PubMed    
    
    
    
32. LAINE L, Sharma P, Mulford DJ, Hunt B, et al
    PHARMACODYNAMICS AND PHARMACOKINETICS OF THE POTASSIUM-COMPETITIVE ACID BLOCKER VONOPRAZAN AND THE PROTON PUMP INHIBITOR LANSOPRAZOLE IN U.S. SUBJECTS.
    Am J Gastroenterol. 2022 Mar 16. pii: 00000434-990000000-00284.
    PubMed     Abstract available
    
    
    January 2022
33. GRAHAM DY, Moss SF
    Antimicrobial susceptibility testing for Helicobacter pylori is now widely available: When, How, Why.
    Am J Gastroenterol. 2022 Jan 25. pii: 00000434-990000000-00227.
    PubMed    
    
    
    December 2021
34. SCHUITENMAKER JM, van Dijk M, Oude Nijhuis RAB, Smout AJPM, et al
    Associations Between Sleep Position and Nocturnal Gastroesophageal Reflux: A Study Using Concurrent Monitoring of Sleep Position and Esophageal pH and Impedance.
    Am J Gastroenterol. 2021 Dec 20. pii: 00000434-990000000-00170.
    PubMed     Abstract available
    
    
    
35. VITOR MS, Tiago LC, Marta F, Tiago CG, et al
    P020 Proton Pump Inhibitor Therapy: Providing "Acid" Outcomes in Patients With Inflammatory Bowel Disease Under Infliximab Treatment.
    Am J Gastroenterol. 2021;116.
    PubMed    
    
    
    
36. MACEDO SILVA V, Lima Capela T, Freitas M, Curdia Goncalves T, et al
    P020 Proton Pump Inhibitor Therapy: Providing "Acid" Outcomes in Patients With Inflammatory Bowel Disease Under Infliximab Treatment.
    Am J Gastroenterol. 2021;116.
    PubMed     Abstract available
    
    
    November 2021
37. KATZ PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, et al
    ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.
    Am J Gastroenterol. 2021 Nov 22. pii: 00000434-990000000-00154.
    PubMed     Abstract available
    
    
    September 2021
38. BHATTACHARYA S, Blau JE, Cochran C, Auh S, et al
    Validity of Secretin Stimulation Testing on Proton Pump Inhibitor Therapy for Diagnosis of Zollinger-Ellison Syndrome.
    Am J Gastroenterol. 2021 Sep 13. pii: 00000434-990000000-00098.
    PubMed     Abstract available
    
    
    August 2021
39. CHENG YY, Tsai MC, Wei JC
    Response to "Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy".
    Am J Gastroenterol. 2021 Aug 27. pii: 00000434-990000000-00086.
    PubMed    
    
    
    
40. LV XH, Wang ZJ, Yang JL
    Proton Pump Inhibitors and COVID-19: Confusing Status Quo.
    Am J Gastroenterol. 2021 Aug 16. pii: 00000434-990000000-00070.
    PubMed    
    
    
    July 2021
41. HE Q, Xia B, Meng W, Fan D, et al
    No Associations Between Regular Use of Proton Pump Inhibitors and Risk of All-Cause and Cause-Specific Mortality: A Population-Based Cohort of 0.44 Million Participants.
    Am J Gastroenterol. 2021 Jul 27. pii: 00000434-990000000-00057.
    PubMed     Abstract available
    
    
    
42. SINGH AD, Zhang X, Anwer F, Bhatt A, et al
    Isolated Gastric Amyloid Light Chain Amyloidosis Causing Upper Gastrointestinal Bleeding.
    Am J Gastroenterol. 2021 Jul 23. pii: 00000434-990000000-00056.
    PubMed    
    
    
    
43. RIBOLSI M, Luca Guarino MP, Balestrieri P, Altomare A, et al
    The Results From Up-Front Esophageal Testing Predict Proton Pump Inhibitor Response in Patients With Chronic Cough.
    Am J Gastroenterol. 2021 Jul 21. pii: 00000434-990000000-00054.
    PubMed     Abstract available
    
    
    
44. LABENZ C, Labenz J
    Proton Pump Inhibitors in Patients With Liver Cirrhosis: Evidence to Improve Their Battered Reputation.
    Am J Gastroenterol. 2021 Jul 19. pii: 00000434-990000000-00048.
    PubMed    
    
    
    
45. ZHANG B, Hu Y, Shi X, Li W, et al
    Integrative Effects and Vagal Mechanisms of Transcutaneous Electrical Acustimulation on Gastroesophageal Motility in Patients With Gastroesophageal Reflux Disease.
    Am J Gastroenterol. 2021;116:1495-1505.
    PubMed     Abstract available
    
    
    June 2021
46. SHIN GY, Park JM, Hong J, Cho YK, et al
    Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
    Am J Gastroenterol. 2021;116:1211-1219.
    PubMed     Abstract available
    
    
    May 2021
47. LIU JJ, Sloan ME, Owings AH, Figgins E, et al
    Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy.
    Am J Gastroenterol. 2021 May 27. pii: 00000434-900000000-98767.
    PubMed     Abstract available
    
    
    
48. WATANABE K, Shimodaira Y, Takahashi S, Fukuda S, et al
    Potent Acid Suppression With Vonoprazan vs Proton Pump Inhibitors Does Not Have Higher Association With Clostridioides difficile Infection.
    Am J Gastroenterol. 2021 May 13. pii: 00000434-900000000-98781.
    PubMed     Abstract available
    
    
    
49. BOTTERI E, Gallus S, Lugo A
    Response to Hoffmeister et al.
    Am J Gastroenterol. 2021;116:1093-1094.
    PubMed    
    
    
    
50. TSAY CJ, Protiva P
    Chronic Mesenteric Ischemia With Peristaltic Blanching.
    Am J Gastroenterol. 2021;116:870.
    PubMed    
    
    
    April 2021
51. NYSSEN OP, Perez-Aisa A, Tepes B, Castro-Fernandez M, et al
    Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg).
    Am J Gastroenterol. 2021 Apr 8. pii: 00000434-900000000-98822.
    PubMed     Abstract available
    
    
    February 2021
52. BISSELING TM, van Laarhoven A, Huijbers A, Brink M, et al
    Coronavirus Disease-19 Presenting as Esophageal Ulceration.
    Am J Gastroenterol. 2021;116:421-424.
    PubMed    
    
    
    January 2021
53. SUGIYAMA T
    Long-Term Safety of Proton Pump Inhibitors: Bone Fracture Risk as an Example.
    Am J Gastroenterol. 2021 Jan 22. pii: 00000434-900000000-98932.
    PubMed    
    
    
    December 2020
54. LISA Y, Robert C
    P051 Proton Pump Inhibitors are Associated with Less Severe Periodontal Disease: Considerations for IBD Patients.
    Am J Gastroenterol. 2020;115.
    PubMed    
    
    
    November 2020
55. ALMARIO CV, Chey WD, Spiegel BMR
    Response to Hajifathalian and Katz Regarding Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors.
    Am J Gastroenterol. 2020;115:1922-1923.
    PubMed    
    
    
    
56. BOUSHEY H, Gonda I
    Comment on Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors.
    Am J Gastroenterol. 2020;115:1921.
    PubMed    
    
    
    
57. TARLOW B, Gubatan J, Khan MA, Cholankeril G, et al
    Are Proton Pump Inhibitors Contributing to SARS-COV-2 Infection?
    Am J Gastroenterol. 2020;115:1920-1921.
    PubMed    
    
    
    
58. HADI YB, Naqvi SF, Kupec JT
    Risk of COVID-19 in Patients Taking Proton Pump Inhibitors.
    Am J Gastroenterol. 2020;115:1919-1920.
    PubMed    
    
    
    
59. HAJIFATHALIAN K, Katz PO
    Regarding "Increased Risk of COVID-19 in Patients Taking Proton Pump Inhibitors".
    Am J Gastroenterol. 2020;115:1918-1919.
    PubMed    
    
    
    
60. ABY ES, Rodin H, Debes JD
    Proton Pump Inhibitors and Mortality in Individuals With COVID-19.
    Am J Gastroenterol. 2020;115:1918.
    PubMed    
    
    
    
61. KOTHARI TH, Enslin S, Cheong J, Kaul V, et al
    Treatment of Bouveret Syndrome Using an Ultrathin Gastroscope: Making the Best out of a Tight Situation!
    Am J Gastroenterol. 2020;115:1748.
    PubMed    
    
    
    October 2020
62. GUO H, Lam AY, Shaheen AA, Forbes N, et al
    Urban-Rural Disparities and Temporal Trends in Peptic Ulcer Disease Epidemiology, Treatment, and Outcomes in the United States.
    Am J Gastroenterol. 2020 Oct 22. doi: 10.14309/ajg.0000000000000997.
    PubMed     Abstract available
    
    
    
63. BOUSHEY H, Gonda I
    Comment on Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors.
    Am J Gastroenterol. 2020 Oct 19. doi: 10.14309/ajg.0000000000001014.
    PubMed    
    
    
    
64. HAJIFATHALIAN K, Katz PO
    Regarding "Increased Risk of COVID-19" in Patients Taking Proton Pump Inhibitors.
    Am J Gastroenterol. 2020 Oct 8. doi: 10.14309/ajg.0000000000000920.
    PubMed    
    
    
    
65. HADI YB, Naqvi SF, Kupec JT
    Risk of COVID-19 in Patients Taking Proton Pump Inhibitors.
    Am J Gastroenterol. 2020 Oct 1. doi: 10.14309/ajg.0000000000000949.
    PubMed    
    
    
    
66. MARTIN TA, Wan DW, Hajifathalian K, Tewani S, et al
    Gastrointestinal Bleeding in Patients With Coronavirus Disease 2019: A Matched Case-Control Study.
    Am J Gastroenterol. 2020;115:1609-1616.
    PubMed     Abstract available
    
    
    September 2020
67. ABY ES, Rodin H, Debes JD
    Proton Pump Inhibitors and Mortality in Individuals With COVID-19.
    Am J Gastroenterol. 2020 Sep 30. doi: 10.14309/ajg.0000000000000992.
    PubMed    
    
    
    
68. HALLAND M, Bharucha AE, Crowell MD, Ravi K, et al
    Effects of Diaphragmatic Breathing on the Pathophysiology and Treatment of Upright Gastroesophageal Reflux: A Randomized Controlled Trial.
    Am J Gastroenterol. 2020 Sep 30. doi: 10.14309/ajg.0000000000000913.
    PubMed     Abstract available
    
    
    May 2020
69. LONGSTRETH GF
    Internists' Misconceptions About PPIs: Increasing Knowledge and Implementing Guidelines.
    Am J Gastroenterol. 2020;115:681-682.
    PubMed     Abstract available
    
    
    
70. BAZERBACHI F, Chandrasekhara V
    Ulcere Perfore-Bouche.
    Am J Gastroenterol. 2020;115:649.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Peptic Ulcer is free of charge.